Journal Publications

Export 124 results:
Author Title [ Type(Asc)] Year
Filters: Type is Journal Article  [Clear All Filters]
Journal Article
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Cain L, Logan R, Robins J, Sterne J, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F et al. Ann Intern Med, 2011 Apr 19, Volume 154, Issue 8, p.509-15, (2011)
What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? Grover D, Copas A, Green H, Edwards S, Dunn D, Sabin C, Phillips A, Allen E and Pillay D. J Antimicrob Chemother, 2008 Mar, Volume 61, Issue 3, p.705-13, (2008)
Virological response to initial antiretroviral regimens containing abacavir or tenofovir. Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J et al. J Infect Dis, 2009 Sep 01, Volume 200, Issue 5, p.710-4, (2009)
Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation. Jose S, Quinn K, Dunn D, Cox A, Sabin C and Fidler S. HIV Med, 2016 May, Volume 17, Issue 5, p.368-72, (2016)
Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women. Huntington S, Bansi L, Thorne C, Anderson J, Newell M, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. BMC Med Res Methodol, 2012 Jul 28, Volume 12, p.110, (2012)
The use of funnel plots with regression as a tool to visually compare HIV treatment outcomes between centres adjusting for patient characteristics and size: a UK Collaborative HIV Cohort study. Gompels M, Michael S, Jose S, Hill T, Trevelion R, Sabin C and May M. HIV Medicine, (2018)
Uptake and outcome of combination antiretroviral therapy in men who have sex with men according to ethnic group: the UK CHIC Study. . J Acquir Immune Defic Syndr, 2012 Apr 15, Volume 59, Issue 5, p.523-9, (2012)
Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? Grant A, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M et al. AIDS, 2009 Nov 27, Volume 23, Issue 18, p.2507-15, (2009)
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, Dorrucci M, Ledergerber B, Mocroft A, Podzamczer D, Cozzi-Lepri A et al. Arch Intern Med, 2010 Mar 08, Volume 170, Issue 5, p.410-9, (2010)
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P, Gilson R, Johnson M et al. HIV Med, 2010 Aug, Volume 11, Issue 7, p.432-8, (2010)
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Costagliola D, Lodwick R, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, De Luca A et al. Lancet Infect Dis, 2012 Feb, Volume 12, Issue 2, p.119-27, (2012)
Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception. Huntington S, Bansi L, Thorne C, Anderson J, Newell M, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. AIDS, 2011 Aug 24, Volume 25, Issue 13, p.1647-55, (2011)
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. Lee K, Dunn D, Gilson R, Porter K, Bansi L, Hill T, Phillips A, Sabin C, Schwenk A, Leen C et al. AIDS, 2008 Oct 01, Volume 22, Issue 15, p.1943-50, (2008)
Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. Sabin C, Hill T, Lampe F, Matthias R, Bhagani S, Gilson R, Youle M, Johnson M, Fisher M, Scullard G et al. BMJ, 2005 Mar 26, Volume 330, Issue 7493, p.695, (2005)
A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada. Patterson S, Jose S, Samji H, Cescon A, Ding E, Zhu J, Anderson J, Burchell A, Cooper C, Hill T et al. HIV Med, 2017 Apr 24, (2017)
Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D and Phillips A. Antivir Ther, 2013, Volume 18, Issue 2, p.213-9, (2013)
The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy. Huntington S, Thorne C, Newell M, Anderson J, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. AIDS, 2015 Nov, Volume 29, Issue 17, p.2269-78, (2015)
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Phillips A, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T, Fisher M, Walsh J et al. Lancet, 2007 Dec 08, Volume 370, Issue 9603, p.1923-8, (2007)
Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Mocroft A, Staszewski S, Weber R, Gatell J, Rockstroh J, Gasiorowski J, Panos G, Monforte A, Rakhmanova A, Phillips A et al. Antivir Ther, 2007, Volume 12, Issue 3, p.325-33, (2007)
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. Kesselring A, Wit F, Sabin C, Lundgren J, M Gill J, Gatell J, Rauch A, Montaner J, de Wolf F, Reiss P et al. AIDS, 2009 Aug 24, Volume 23, Issue 13, p.1689-99, (2009)
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). Mocroft A, Lundgren J, Sabin M, Monforte A, Brockmeyer N, Casabona J, Castagna A, Costagliola D, Dabis F, De Wit S et al. PLoS Med, 2013, Volume 10, Issue 9, p.e1001510, (2013)
Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters. Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C, Bansi L, Gompels M et al. HIV Med, 2011 May, Volume 12, Issue 5, p.289-98, (2011)
Response to combination antiretroviral therapy: variation by age. Sabin C, Smith C, Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A et al. AIDS, 2008 Jul 31, Volume 22, Issue 12, p.1463-73, (2008)
Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women. Huntington S, Thorne C, Anderson J, Newell M, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. BMC Infect Dis, 2014 Mar 04, Volume 14, p.127, (2014)
Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. Bouteloup V, Sabin C, Mocroft A, Gras L, Pantazis N, Le Moing V, Monforte A, Mary-Krause M, Roca B, Miro J et al. HIV Med, 2017 Jan, Volume 18, Issue 1, p.33-44, (2017)